Researchers studied the effect of dapagliflozin on cumulative sodium excretion in patients with type 2 diabetes and preserved kidney function while sodium intake was being strictly controlled.
Improving the cardiovascular health of patients and the general population requires increased primordial and primary prevention efforts.
The effects of combined verinurad and febuxostat treatment were independent of blood pressure.
Improvements seen in glycemic, blood pressure, lipid control within the population partly explain decrease in albuminuria
Greatest CAN prevention effect seen among type 2 diabetes patients without cardiovascular disease history.
Five cases of euDKA identified in patients with type 2 diabetes using SGLT2 inhibitors who developed SARS-CoV-2 infection.
One-year increase in age at diabetes diagnosis linked to lower risk for all-cause mortality and macrovascular, microvascular disease.
Risk for severe COVID-19 similar among those with type 1 and type 2 diabetes
In overall sample of men and women, metformin use was not linked to significantly reduced mortality
The alert was based on data from three 20-week double-blind, placebo-controlled studies each with 34-week extensions.
